Cancer Biologics Market

Global Cancer Biologics Market Size (2024 to 2029)

The global cancer biologics market is expected to be worth USD 178.48 billion by 2029 from USD 108.44 billion in 2024, growing at a CAGR of 10.48% from 2024 to 2029.

MARKET DRIVERS

The growing incidence and prevalence of cancer worldwide majorly drive the cancer biologics market growth.

According to the World Health Organisation (WHO), cancer is a major cause of illness and mortality globally with millions of new cases identified each year. As the incidence of cancer rises, so does the demand for effective treatment options such as cancer biologics. As a result, pharmaceutical companies are investing heavily in the development of innovative biological therapies to satisfy the unmet needs of cancer patients.

The growing number of advancements in the biotechnology and genetic engineering fields contributes to the growth of the cancer biologics market.

These advancements have dramatically transformed the field of cancer biologics by enabling the development of highly focused and personalized treatments. Biotechnology has made it possible to create monoclonal antibodies, immune checkpoint inhibitors, and other biologic drugs. These advancements have resulted in improved treatment outcomes and fewer side effects than traditional chemotherapy, accelerating the adoption of cancer biologics in the healthcare industry.

The growing awareness and rapid adoption of personalized medicine favor the cancer biologics market growth.

The rising demand for personalized medicine has expedited the uptake of cancer biologics. Every cancer is unique, with its own set of genetic mutations and characteristics. Cancer biologics have the advantage of giving targeted therapy that can be tailored to each patient's specific genetic or biomarker profile, allowing for more accurate and efficient therapy. The growing number of alliances and strategic partnerships between pharmaceutical companies, academic institutions and biotechnology companies have also assisted the growth of the cancer biologics sector. These collaborations pool resources, expertise and technology to accelerate the development of better and more effective cancer biologics.

The rising demand for targeted therapies, favorable regulatory policies and expedited approval processes for cancer biologics, increasing investments in R&D activities by pharmaceutical companies and research institutions and growing preference for immunotherapies propel the cancer biologics market growth. The rise in healthcare spending, especially in emerging economies and continually expanding their indications and targeting new therapeutic targets of cancer biologics further boost the growth rate of the cancer biologics market.

MARKET RESTRAINTS

The high costs associated with cancer biologics are one of the major impediments to the cancer biologics market.

According to a study published in the Journal of Clinical Oncology, the cost of cancer biologics can range from thousands to tens of thousands of dollars per month. The high cost of treatment causes financial hurdles for patients with inadequate health insurance coverage, especially in low-income countries. Stringent regulatory requirements for the approval of cancer biologics, inadequate reimbursement policies or restrictions imposed by healthcare payers, and complex manufacturing processes involved in producing biologics, including cell culture and purification and intellectual property rights and patent exclusivity for biologics further hinder the market growth. Concerns about potential adverse effects and safety profiles of cancer biologics, limited availability of long-term clinical data for some cancer biologics, specialized infrastructure and storage conditions required for the storage and transportation of biologics, regulatory changes and uncertainties in different regions or countries and intense competition from existing and emerging cancer therapies predicts to have a negative impact on the cancer biologics market growth in the coming years.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Cancer Biologics Market Analysis By Type

The monoclonal antibodies segment is predicted to account for the major share of the global market and witness the highest CAGR during the forecast period. The growing global cancer prevalence, increased emphasis on genomics R&D and introduction of breakthrough genetic technologies such as next-generation sequencing propel the growth of the monoclonal antibodies segment in the worldwide market. The affordability of the technologies required to create mAbs for research, the increased patient and clinician awareness of mAbs therapy applications and better availability of medicines further contribute to the segmental growth.

The vaccine segment is estimated to capture a considerable share of the worldwide market during the forecast period. Factors such as the rising focus on preventive measures and cancer vaccination programs, potential to prevent certain types of cancer and reduce disease burden and the growing investments in vaccine development for cancer treatment and prevention drive the growth of the vaccines segment in the global market.

Global Cancer Biologics Market Analysis By Application

The breast cancer segment is anticipated to occupy the major share of the global market during the forecast period owing to the high prevalence of breast cancer globally and growing awareness and screening programs for early detection. Advancements in targeted therapies specifically for breast cancer, supportive regulatory environment for breast cancer treatments and rapid adoption of personalized medicine approaches for breast cancer further contributes to the growth of the breast cancer segment in the global cancer biologics market.

The non-small cell lung cancer segment is expected to witness a healthy CAGR during the forecast period. The non-small cell lung cancer is the most common type of lung cancer. The growing number of advancements in immunotherapies and targeted therapies for non-small cell lung cancer, rising smoking rates and exposure to environmental carcinogens drive the segmental growth. The rising emphasis on early detection and screening programs and increasing research and development activities for lung cancer treatments fuels the segment’s growth rate.

Global Cancer Biologics Market Analysis By Distribution Channel

The hospital segment is expected to hold the leading share of the global market during the forecast period. The availability of comprehensive cancer care facilities and specialized oncology departments, access to a wide range of cancer biologics and advanced treatment options and collaboration with research institutions and clinical trials for innovative cancer therapies majorly drive the growth of the hospitals segment.

REGIONAL ANALYSIS

North America is a dominant region in the cancer biologics market and is primarily driven by the presence of advanced healthcare infrastructure, strong research and development activities and high healthcare expenditure. The growing prevalence of cancer and increasing incidence rates, favorable reimbursement policies for cancer treatments, increasing research and development activities in the field of cancer biologics, the presence of key biopharmaceutical companies and strong regulatory framework for drug approvals further fuel the growth rate of the North American market. The U.S. market holds the major share of the North American market during the forecast period due to the presence of major pharmaceutical companies and a large patient pool. Biologics are used to treat about 70% of breast cancer cases and 55% of colorectal cancer cases.

However, the Asia Pacific region is expected to witness the highest CAGR among all the regions worldwide in the coming years. Factors such as a large patient population, increasing healthcare expenditure and rising adoption of advanced therapies majorly drive the APAC market growth.  More than 40 biosimilars were reportedly in the clinical development stage in India, according to recent studies. Twenty to twenty-five individuals with newly discovered breast cancer in China are receiving biological therapy. Rapidly growing population, increasing prevalence of cancer, rising awareness about cancer diagnosis and treatment options, improving access to advanced cancer therapies, emerging markets with untapped potential and initiatives from the governments of APAC countries to improve cancer care and access to biologics further propel the APAC market growth. China and Japan are projected to have control over the major share of the APAC market during the forecast period.

Europe is another promising regional market for cancer biologics and is anticipated to hold a substantial share of the worldwide market during the forecast period. The growing adoption of targeted therapies and immunotherapies, increasing support from the governments of European countries for cancer research and treatment, rising prevalence of cancer in Europe and collaborations between research institutions and biopharmaceutical companies drive the cancer biologics market growth in Europe. The availability of advanced healthcare facilities and stringent regulations for drug safety and efficacy further boost the European market growth. Germany accounted for the major share of the European market in 2022.

Latin America is expected to register a steady CAGR during the forecast period. Factors such as the growing healthcare spending, improving healthcare infrastructure, rising awareness about early cancer detection and treatment, growing availability of biologics through public healthcare systems and expansion of market presence by biopharmaceutical companies support the Latin American market growth.

MEA is anticipated to account for a moderate share of the global market during the forecast period.

KEY PLAYERS IN THE GLOBAL CANCER BIOLOGICS MARKET

Roche Holdings AG, Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Johnson & Johnson, Pfizer Inc., Amgen Inc., AstraZeneca plc, Eli Lilly and Company and AbbVie Inc. are playing a leading role in the global cancer biologics market.

RECENT HAPPENINGS IN THE MARKET

• In June 2023, a new case report details a complete pathological response to a 3-month combination therapy of ixazomib, bendamustine, and dexamethasone (IBd) in a 68-year-old patient with multiple myeloma and an incidental cT1b (9 mm) hormone receptor (HR)–positive breast cancer lesion. It was found that Ixazomib and bendamustine did not synergise in invasive HR-positive breast cancer cell lines, and Ixazomib inhibits cell proliferation in a dose-dependent fashion. Because of this, the researchers hypothesised that ixazomib alone, not bendamustine, "was solely responsible for tumour regression in our patient." Researchers believed ixazomib could be a chemotherapy-free biological therapeutic.

DETAILED SEGMENTATION OF THE GLOBAL CANCER BIOLOGICS MARKET INCLUDED IN THIS REPORT

This research report on the global cancer biologics market has been segmented and sub-segmented based on type, application, distribution channel, and region.

By Type

• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other Types

By Application

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Other Applications

By Distribution Channel

• Hospitals
• Clinics
• Other Distribution Channels

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa